Stay updated on Nivolumab After SIRT for HCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.

Latest updates to the Nivolumab After SIRT for HCC Clinical Trial page
- Check4 days agoChange DetectedThe NASIR-HCC study page shows only minor UI adjustments (spacing/formatting) with no changes to study details or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check12 days agoNo Change Detected
- Check33 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check40 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0; no other content changes provided.SummaryDifference0.1%

- Check55 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2 and removed the Back to Top element. Overall, core content, pricing, stock/slot availability, and proper nouns remain unchanged.SummaryDifference0.2%

- Check62 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.SummaryDifference0.2%

- Check69 days agoChange DetectedThe web page has undergone significant updates, including the addition of a facility name and location in Barakaldo, Spain, as well as new research references related to liver cancer treatment. Notably, several terms related to immunological agents have been removed.SummaryDifference7%

Stay in the know with updates to Nivolumab After SIRT for HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab After SIRT for HCC Clinical Trial page.